The safety debate around compounded semaglutide has become deeply political. Novo Nordisk (which sells brand-name Wegovy at $349/month) has a financial incentive to discredit compounded alternatives. The FDA has issued warnings. Lawsuits are flying. Meanwhile, millions of patients are using compounded semaglutide at $119–199/month and reporting positive experiences.
This article isn't here to sell you on compounded or scare you away from it. It's here to separate the facts from the spin.
What the FDA Has Actually Said
The FDA has issued multiple communications about compounded semaglutide. Here's what they've actually stated — and what they haven't:
What the FDA HAS said:
- Compounded semaglutide products are not FDA-approved
- The FDA has identified dosing errors with some compounded products that led to hospitalizations
- Some compounded products have used semaglutide sodium salt (a different chemical form) rather than semaglutide base
- The FDA has sent warning letters to specific compounding pharmacies for quality violations
What the FDA has NOT said:
- The FDA has not said that all compounded semaglutide is unsafe
- The FDA has not banned compounded semaglutide
- The FDA has not said that licensed 503A/503B pharmacies cannot legally compound semaglutide
- The FDA has not issued a recall of compounded semaglutide as a class
Real Risks to Understand
1. Potency Variability
Brand-name Wegovy is manufactured under strict FDA-mandated quality controls with batch-to-batch consistency. Compounded semaglutide is prepared by compounding pharmacies with variable quality standards. 503B outsourcing facilities (registered with FDA) have more rigorous testing than 503A pharmacies. Ask your provider which type of pharmacy they use.
2. Dosing Accuracy
The FDA has documented cases where compounded semaglutide had incorrect concentrations — leading to patients receiving too much or too little medication. This is a real risk, particularly with 503A pharmacies that may not test every batch.
3. Chemical Form
Some compounded products use semaglutide sodium salt rather than semaglutide base. The FDA has raised concerns that these are not the same compound and haven't been tested for safety and efficacy in the same way.
How to Minimize Risk With Compounded GLP-1s
- Verify pharmacy licensing: Ask whether your provider uses a 503A or 503B pharmacy. 503B facilities undergo FDA inspections and test every batch.
- Ask for certificates of analysis: Reputable pharmacies will provide potency and sterility testing results for their products.
- Check for LegitScript certification: An independent verification that screens pharmacies against regulatory standards.
- Start with a low dose: Standard protocol — but especially important with compounded products to verify your body's response before titrating up.
- Use established providers: Providers with large patient bases (100K+ prescriptions) have more pharmacy oversight and accountability.
Providers We've Verified
| Provider | Starting Price | Prescriptions Filled | Details |
|---|---|---|---|
| Get Thin MD | $119/mo | 110,000+ | Check Price → Paid link |
| Yucca Health | $149/mo | Established | Check Price → Paid link |
| Novi | $174/mo | 100,000+ | Check Price → Paid link |
Prefer Brand-Name?
| Provider | Starting Price | Details |
|---|---|---|
| Sesame Care | from $199 | Check Price → Paid link |
Key Takeaways
- Compounded semaglutide is legal, widely used, and effective for millions of patients
- Real risks exist: potency variability, dosing accuracy, and less manufacturing oversight
- 503B pharmacies (FDA-registered) are safer than 503A pharmacies
- The FDA has not banned compounded semaglutide or declared it universally unsafe
- Novo Nordisk's lawsuits are commercial disputes, not safety actions
- If safety is your top concern, oral Wegovy ($149/mo) and Sesame Care offer FDA-approved options
Compare All GLP-1 Prices
See today's lowest verified prices from vetted telehealth providers.
Compare Prices →